Close menu




May 5th, 2021 | 09:14 CEST

Infineon, Triumph Gold, Ballard Power - Invest in the future now!

  • Investments
Photo credits: pixabay.com

The earnings season is in full swing. In addition to Corona winners such as TeamViewer or Zalando, which continue to profit from the consequences of the pandemic, biotech companies working to combat the virus also shine with solid figures. On the other hand, companies directly involved in the energy turnaround are disappointing at first glance. In addition to electric carmakers currently struggling with production stoppages due to the acute global chip shortage, renewable energy stocks have also missed analysts' forecasts.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: DE0006231004 , CA8968121043 , CA0585861085

Table of contents:


    Triumph Gold - Best conditions

    The conditions for a rising gold price could not be better. Rising inflation due to the ever-inflating money supply and historical debt levels provide a healthy long-term breeding ground for the precious yellow metal. Moreover, gold miners are in better fundamental shape than ever after a record 2020 and are sitting on mountains of cash to invest in new projects. Interesting second-tier mine operators with substantial assets abound due to the wave of consolidation that has been underway since August.

    One diamond in the rough is the exploration Company Triumph Gold. The Canadians, in which heavyweight Newmont already has a 12.8% stake, operate the Freegold Mountain project in the Dawson Range gold belt of Yukon. The project covers an extensive area of the Big Creek fault zone, a structure directly associated with epithermal gold and silver mineralization and gold-bearing porphyry copper mineralization.

    Recently, Triumph Gold additionally secured the Big Creek property, which is believed to host gold and copper. The property consists of 258 contiguous quartz mining claims in Yukon's Whitehorse Mining District. Drilling programs are expected to begin here in the spring. With about CAD 5 million in cash, Triumph Gold is funded for the entire year. Currently, the stock is forming a floor around CAD 0.16. With an expected friendly gold market, the Canadians should benefit disproportionately.

    Ballard Power - Worse than feared

    Yesterday, the Canadian manufacturer of fuel cells, Ballard Power, was brought back to earth. The Company, based in Burnaby near Vancouver, British Columbia, completely collapsed compared to the same period last year and missed analysts' already less euphoric estimates for both sales and losses. Revenue of USD 17.6 million was a crisp 26% below the first quarter of 2020, while analyst firms on average were expecting revenue around USD 25 million. Loss per share was also below forecasts at USD 0.06. The gross margin came in at 15%.

    Despite the weak results, management is well prepared for the future. The reason is the bulging war chest of USD 1.3 billion. Ballard Power CEO Randy MacEwen plans to attack this during the year and accelerate investments in technology, products, advanced manufacturing and localization. The Canadians are seeing growing interest, particularly in fuel cell buses in Europe. As a result, follow-up orders were captured from Wrightbus and Solaris. In the truck market, joint development work was advanced with the Weichai-Ballard joint venture in China and with MAHLE on a fuel cell engine for the European market.

    Also announced earlier this week was a strategic collaboration with Linamar focused on powertrains and components for the Class 1 and Class 2 vehicle markets in North America and Europe. Overall, the Company sees 2021 as a transition year with high investments to be prepared for strong long-term growth.

    Infineon - Better than expected

    Chip manufacturer Infineon, on the other hand, raised its forecast. The semiconductor market, which has exploded, and the continuing recovery in the automotive industry, keep the profits of the Neubiberg-based Company flowing. Management expects sales of around EUR 11.0 billion for the full year 2021. Capital expenditure is expected to remain at EUR 1.6 billion for the full year. The operating margin has also been raised from 17.5% to 18%.

    The reason for the optimism lies in the excess demand in almost all segments. Electronics for accelerating the energy transition and for work and home life, for example, remain in high demand. Despite the positive news, the price of Infineon shares went south by more than 4%, trading at EUR 32.20. The outlook for the current third fiscal quarter was solid for market participants, but it no longer came as a surprise and was therefore already priced into the share price.

    In the 32 area, there is a striking support zone that has been formed since the beginning of the year. Should this zone be sustainably broken, the next target would be a run to the EUR 28 range.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read